CA3055006C - Influenza virus mutants and uses therefor - Google Patents

Influenza virus mutants and uses therefor Download PDF

Info

Publication number
CA3055006C
CA3055006C CA3055006A CA3055006A CA3055006C CA 3055006 C CA3055006 C CA 3055006C CA 3055006 A CA3055006 A CA 3055006A CA 3055006 A CA3055006 A CA 3055006A CA 3055006 C CA3055006 C CA 3055006C
Authority
CA
Canada
Prior art keywords
virus
atm
influenza
ferrets
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3055006A
Other languages
English (en)
French (fr)
Other versions
CA3055006A1 (en
Inventor
Pamuk Bilsel
Yasuko Hatta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FluGen Inc
Original Assignee
FluGen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47423213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3055006(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by FluGen Inc filed Critical FluGen Inc
Priority to CA3103774A priority Critical patent/CA3103774A1/en
Publication of CA3055006A1 publication Critical patent/CA3055006A1/en
Application granted granted Critical
Publication of CA3055006C publication Critical patent/CA3055006C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16261—Methods of inactivation or attenuation
    • C12N2760/16262—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA3055006A 2011-06-24 2012-06-21 Influenza virus mutants and uses therefor Active CA3055006C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3103774A CA3103774A1 (en) 2011-06-24 2012-06-21 Influenza virus mutants and uses therefor

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161501034P 2011-06-24 2011-06-24
US61/501,034 2011-06-24
CA2875484A CA2875484C (en) 2011-06-24 2012-06-21 Influenza virus mutants and uses therefor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2875484A Division CA2875484C (en) 2011-06-24 2012-06-21 Influenza virus mutants and uses therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3103774A Division CA3103774A1 (en) 2011-06-24 2012-06-21 Influenza virus mutants and uses therefor

Publications (2)

Publication Number Publication Date
CA3055006A1 CA3055006A1 (en) 2012-12-27
CA3055006C true CA3055006C (en) 2021-02-09

Family

ID=47423213

Family Applications (4)

Application Number Title Priority Date Filing Date
CA3055006A Active CA3055006C (en) 2011-06-24 2012-06-21 Influenza virus mutants and uses therefor
CA3103774A Abandoned CA3103774A1 (en) 2011-06-24 2012-06-21 Influenza virus mutants and uses therefor
CA2875484A Active CA2875484C (en) 2011-06-24 2012-06-21 Influenza virus mutants and uses therefor
CA3055002A Active CA3055002C (en) 2011-06-24 2012-06-21 Influenza virus mutants and uses therefor

Family Applications After (3)

Application Number Title Priority Date Filing Date
CA3103774A Abandoned CA3103774A1 (en) 2011-06-24 2012-06-21 Influenza virus mutants and uses therefor
CA2875484A Active CA2875484C (en) 2011-06-24 2012-06-21 Influenza virus mutants and uses therefor
CA3055002A Active CA3055002C (en) 2011-06-24 2012-06-21 Influenza virus mutants and uses therefor

Country Status (11)

Country Link
US (7) US9284533B2 (cg-RX-API-DMAC10.html)
EP (3) EP4023749A1 (cg-RX-API-DMAC10.html)
JP (7) JP6253576B2 (cg-RX-API-DMAC10.html)
KR (7) KR102080062B1 (cg-RX-API-DMAC10.html)
CN (3) CN106995802B (cg-RX-API-DMAC10.html)
AU (5) AU2012272837B2 (cg-RX-API-DMAC10.html)
CA (4) CA3055006C (cg-RX-API-DMAC10.html)
DK (2) DK3447131T3 (cg-RX-API-DMAC10.html)
ES (1) ES2890427T3 (cg-RX-API-DMAC10.html)
MX (4) MX346625B (cg-RX-API-DMAC10.html)
WO (1) WO2012177924A2 (cg-RX-API-DMAC10.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3169427B2 (ja) 1992-04-07 2001-05-28 新日本製鐵株式会社 磁気特性の優れた二方向性珪素鋼板の製造方法
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
JP2013507990A (ja) 2009-10-26 2013-03-07 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
EP2590971A4 (en) 2010-06-17 2014-12-10 Fuzians Biomedicals Inc COMPOUNDS SUITABLE FOR ANTIVIRAL ACTIVE SUBSTANCES, COMPOSITIONS AND METHOD OF USE THEREOF
CN106995802B (zh) 2011-06-24 2021-04-09 复尔健有限公司 流感病毒突变体及其用途
ES2655051T3 (es) 2011-08-26 2018-02-16 Wisconsin Alumni Research Foundation Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas
CN104056276B (zh) * 2013-03-20 2017-05-10 上海生物制品研究所有限责任公司 一种流感病毒减毒活疫苗及其制备方法
JP2016524915A (ja) 2013-07-15 2016-08-22 ウィスコンシン アルムニ リサーチ ファンデイション Ｍｄｃｋ、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス
US9757446B2 (en) * 2014-03-17 2017-09-12 Flugen, Inc. Influenza virus vectors and uses therefor
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
JP2019510481A (ja) 2016-02-19 2019-04-18 ウィスコンシン アルムニ リサーチ ファンデイション ワクチン開発のための改善されたｂ型インフルエンザウイルス複製
CN110573614B (zh) 2017-02-27 2024-03-29 复尔健有限公司 针对流感的免疫原性组合物
CN118272323A (zh) * 2017-02-27 2024-07-02 复尔健有限公司 流感b病毒突变体及其用途
CN107151659B (zh) * 2017-03-01 2021-04-02 苏州系统医学研究所 一种流感病毒株及其应用
WO2019084310A1 (en) 2017-10-25 2019-05-02 Yoshihiro Kawaoka HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
US11389523B2 (en) 2018-08-20 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
EP3914295A2 (en) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
KR102370100B1 (ko) 2019-02-15 2022-03-07 아이디바이오 주식회사 이종 인플루엔자 a 바이러스에 대한 면역/치료반응을 형성하는 신규한 재조합 인플루엔자 바이러스 및 이를 포함하는 유전자 전달체 및 치료백신
US11214799B2 (en) 2019-03-12 2022-01-04 The University Court Of The University Of Edinburg Old College HA-specific influenza virus attenuated vaccine comprising mutations in segment 7, and uses therefor
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
EP3980060A4 (en) 2019-06-07 2023-04-12 Flugen, Inc. FLU VIRUS BACKBONE
CN110468130B (zh) * 2019-08-09 2021-08-06 中国人民解放军军事科学院军事医学研究院 流感长链非编码RNA-lnc330及其应用
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
JP2023511444A (ja) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたｎａを有する組換えインフルエンザウイルス
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
WO2022020469A1 (en) 2020-07-21 2022-01-27 Flugen, Inc. Influenza virus backbone
CN114381438B (zh) * 2022-01-27 2024-02-02 浙江迪福润丝生物科技有限公司 一种流感病毒的致弱方法及流感致弱病毒株和应用
CN114410681B (zh) * 2022-01-27 2024-02-13 浙江迪福润丝生物科技有限公司 一种基于m基因核苷酸片段删除的流感病毒的致弱方法以及致弱流感病毒株和应用
CN114438043B (zh) * 2022-01-27 2023-12-15 浙江迪福润丝生物科技有限公司 一种区分感染和免疫的致弱流感病毒疫苗株及疫苗
CN114381439B (zh) * 2022-01-27 2023-12-15 浙江迪福润丝生物科技有限公司 一种同义突变结合删除突变的流感病毒的致弱方法及致弱流感病毒株和应用
CN114381440B (zh) * 2022-01-27 2023-12-15 浙江迪福润丝生物科技有限公司 一组基于同义突变和/或缺失突变的a型流感病毒致弱毒株及其制备方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6253576U (cg-RX-API-DMAC10.html) 1985-09-21 1987-04-02
JPH05515Y2 (cg-RX-API-DMAC10.html) 1987-12-16 1993-01-08
CA2275605A1 (en) * 1996-12-20 1998-07-02 The Procter & Gamble Company A dry laid structure comprising particulate material
GB9815040D0 (en) * 1998-07-10 1998-09-09 Medical Res Council Conditional mutant
AU5533601A (en) * 2000-04-14 2001-10-30 Wisconsin Alumni Res Found Viruses comprising mutation ion channel protein
EP1364006A2 (en) 2001-02-23 2003-11-26 Wisconsin Alumni Research Foundation Methods to identify mutant cells with altered sialic acid
JP2007525175A (ja) * 2003-04-23 2007-09-06 ウィスコンシン アルムニ リサーチ ファウンデイション 突然変異した膜タンパク質をその機能性の一部ウイルス
ES2593082T3 (es) * 2003-05-28 2016-12-05 Wisconsin Alumni Research Foundation Virus de la gripe recombinantes a título elevado para vacunas y terapia génica
CA2536249A1 (en) * 2003-08-25 2005-03-10 3M Innovative Properties Company Delivery of immune response modifier compounds
CN1810961B (zh) * 2006-02-22 2010-05-12 中国人民解放军军事医学科学院微生物流行病研究所 一种重组流感病毒及其制备方法与应用
US9474798B2 (en) * 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
AU2008321016B2 (en) * 2007-11-12 2013-03-28 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
EP2296701A1 (en) 2008-06-11 2011-03-23 Flugen, Inc. Cell-based systems for producing influenza vaccines
US20100061995A1 (en) * 2008-09-08 2010-03-11 Damian Michael Carragher Immunotherapy To Treat Or Prevent Viral Infection
KR20120018783A (ko) * 2009-05-01 2012-03-05 레드바이오텍 아게 다중 유전자 벡터에 의해 암호화된 재조합 바이러스-유사 입자
US20110172637A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Drug delivery device including tissue support structure
US20110172639A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Device and method for delivery of microneedle to desired depth within the skin
US20110172609A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Microneedle component assembly for drug delivery device
US20110172638A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Drug delivery device including multi-functional cover
US20110172645A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Wearable drug delivery device including integrated pumping and activation elements
US8668675B2 (en) 2010-11-03 2014-03-11 Flugen, Inc. Wearable drug delivery device having spring drive and sliding actuation mechanism
TW201303143A (zh) 2011-03-22 2013-01-16 Exxonmobil Upstream Res Co 低排放渦輪機系統中用於攫取二氧化碳及產生動力的系統與方法
CN106995802B (zh) 2011-06-24 2021-04-09 复尔健有限公司 流感病毒突变体及其用途
JP6639334B2 (ja) 2016-06-20 2020-02-05 株式会社日立製作所 業務処理フロー生成システム、生成方法および装置
JP6120237B1 (ja) 2016-06-20 2017-04-26 仁博 平嶋 サービスシステム、アプリケーションプログラム及び決済方法

Also Published As

Publication number Publication date
JP2019103516A (ja) 2019-06-27
JP6870017B2 (ja) 2021-05-12
AU2012272837A2 (en) 2014-01-30
CN103781901A (zh) 2014-05-07
JP2025066111A (ja) 2025-04-22
KR102275459B1 (ko) 2021-07-09
JP2023071764A (ja) 2023-05-23
KR102446975B1 (ko) 2022-09-22
ES2890427T3 (es) 2022-01-19
JP2014526883A (ja) 2014-10-09
NZ620242A (en) 2016-02-26
AU2023204165A1 (en) 2023-08-03
AU2012272837A1 (en) 2014-01-16
KR102628482B1 (ko) 2024-01-23
AU2018200490B2 (en) 2020-03-19
JP6496000B2 (ja) 2019-04-03
JP6445662B2 (ja) 2018-12-26
KR20200021100A (ko) 2020-02-27
MX2014000254A (es) 2014-10-14
CA2875484C (en) 2019-11-05
US11207399B2 (en) 2021-12-28
CA3055002C (en) 2021-02-09
DK3447131T3 (da) 2021-09-13
US20250090649A1 (en) 2025-03-20
US9284533B2 (en) 2016-03-15
US20160228534A1 (en) 2016-08-11
CN103781901B (zh) 2019-04-12
CN109652430A (zh) 2019-04-19
MX2021006342A (es) 2022-05-26
CA3055006A1 (en) 2012-12-27
CN109652430B (zh) 2023-05-16
AU2018200490A1 (en) 2018-02-15
US20160228535A1 (en) 2016-08-11
KR20180094147A (ko) 2018-08-22
EP4023749A1 (en) 2022-07-06
DK2723855T3 (en) 2018-10-01
WO2012177924A2 (en) 2012-12-27
EP3447131A1 (en) 2019-02-27
US9919043B2 (en) 2018-03-20
CA2875484A1 (en) 2012-12-27
KR102080061B1 (ko) 2020-02-21
US9919042B2 (en) 2018-03-20
CA3055002A1 (en) 2012-12-27
EP2723855A4 (en) 2015-01-07
US11040098B2 (en) 2021-06-22
AU2018200488A1 (en) 2018-02-08
KR102080062B1 (ko) 2020-02-21
AU2018200488B2 (en) 2020-03-19
AU2020201760B2 (en) 2023-04-20
KR20210084710A (ko) 2021-07-07
EP3447131B1 (en) 2021-08-18
AU2012272837B2 (en) 2017-11-02
MX361139B (es) 2018-11-28
KR20140037235A (ko) 2014-03-26
US20220409719A1 (en) 2022-12-29
JP2018046850A (ja) 2018-03-29
KR20220133316A (ko) 2022-10-04
US11980661B2 (en) 2024-05-14
CN106995802A (zh) 2017-08-01
US20190060441A1 (en) 2019-02-28
JP2018046851A (ja) 2018-03-29
EP2723855A2 (en) 2014-04-30
CA3103774A1 (en) 2012-12-27
JP2021112196A (ja) 2021-08-05
KR102080914B1 (ko) 2020-02-26
AU2020201760A1 (en) 2020-03-26
US20140127249A1 (en) 2014-05-08
JP7231666B2 (ja) 2023-03-01
KR20240013286A (ko) 2024-01-30
JP6253576B2 (ja) 2017-12-27
EP2723855B1 (en) 2018-08-08
MX346625B (es) 2017-03-27
CN106995802B (zh) 2021-04-09
WO2012177924A3 (en) 2013-09-06
US20200061182A1 (en) 2020-02-27
MX383065B (es) 2025-03-13
KR20180094145A (ko) 2018-08-22

Similar Documents

Publication Publication Date Title
US11980661B2 (en) Influenza virus mutants and uses therefor
WO2015142671A2 (en) Influenza virus vectors and uses therefor
EP3585885A1 (en) Immunogenic compositions against influenza
HK40076573A (en) Influenza a virus mutants
HK40005266A (en) Influenza a virus mutants
HK40005266B (en) Influenza a virus mutants
NZ620242B2 (en) Influenza virus mutants and uses therefor

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190911

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251014

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260204

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260804